Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030 (Source: The Oncologist)
Source: The Oncologist - March 7, 2024 Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030 (Source: The Oncologist)
Source: The Oncologist - March 7, 2024 Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research

Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
CONCLUSION: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.PMID:38431780 | DOI:10.1093/oncolo/oyae031 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Zuzana Bielcikova Milos Holanek Iveta Selingerova Ondrej Sorejs Iveta Kolarova Renata Soumarova Jan Proks Lucie Reifova Vlastimila Cmejlova Lenka Linkova Michaela Zabojnikova Martina Chodacka Lucie Janovska Lenka Lisnerova Karolina Kasparova Denisa Pohank Source Type: research

Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer
CONCLUSION: PLR and NLR could be used to predict the efficacy of neoadjuvant therapy with the taxane, anthracycline, and lobaplatin regimen for patients with TNBC, as patients who had lower PLR and NLR values had a higher tpCR rate and a better long-term prognosis.PMID:38431781 | DOI:10.1093/oncolo/oyae025 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Cheng Wang Qiyun Shi Guozhi Zhang Xiujuan Wu Wenting Yan Andi Wan Siyi Xiong Long Yuan Hao Tian Dandan Ma Jun Jiang Xiaowei Qi Yi Zhang Source Type: research

Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis
CONCLUSION: Patient's SB seems to carry a prognostic significance. ESAS and physician-reported ECOG exhibit comparable prognostic values. Physicians and patients can frequently have divergent opinions on PS. ESAS takes a patient-centered approach and should be encouraged in practice among patients with GEC as an additional tool for prognostication.PMID:38431782 | DOI:10.1093/oncolo/oyae010 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Thais Baccili Cury Megid Divya Sharma Zeynep Baskurt Lucy Xiaolu Ma Xin Wang Carly C Barron Raymond Woo-Jun Jang Eric Xueyu Chen Carol Jane Swallow Aruz Mesci Jonathan Yeung Rebecca K S Wong Savtaj Singh Brar Patrick Veit-Haibach John Kim Yvonne Bach Hiro Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research